References

The Revised Authoritative Guide To Vaccine Legal Exemptions

Vaccines Have Serious Side Effects

Get Instant Access

1. Asadullah, K., Sterry, W., Volk, H.D. Interleukin-10 therapy - review of a new approach. Pharmacol. Rev. 2003; 55:241-269.

2. Bangia, N., Ferrone, S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: Do they provide tumor cells with escape mechanisms from recognition by cytotoxic Tlymphocytes? Immunol. Invest. 2006; 35:485-503.

3. Basler, M., Youhnovski, N., Van Den, B. M., Przybylski, M., Groettrup, M. Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningi-tis virus. J. Immunol. 2004; 173:3925-3934.

4. Chang, C. C., Campoli, M., Ferrone, S. Classical and nonclassical HLA class Iantigen and NK cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 2005: 93189-93234.

5. Conrad, C. T., Ernst, N. R., Dummer, W,, Bröcker, E. B., Becker, J. C. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J. Exp. Clin. Cancer Res. 1999; 18:225-232.

6. Contini, P., Ghio, M., Poggi, A., Filaci, G., Indiveri, F., Ferrone, S., Puppo, F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 2003; 33:125-134.

7. Dovhey, S. E., Ghosh, N. S., Wright, K. L. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line. Cancer Res. 2002; 60:5789-5796.

8. Eisele, G., Wischhusen, J., Mittelbronn, M., Meyermann, R., Waldhauer, I., Steinle, A., Weller, M., Friese, M. A. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain. 2006; 129:2416-2425.

9. Ferris, R., Whiteside, T. L., Ferrone, S. Immune escape associated with functional defects in antigen processing machinery in head and neck cancer. Clin. Cancer Res. 2006; 12:3890-3895.

10. Fournel, S., Aguerre-Girr, M., Huc, X., Lenfant, F., Alam, A., Toubert, A., Bensussan, A., Le Bouteiller, P. Cutting edge: soluble HLA-G1 triggers CD95/CD95 ligand-mediated apoptosis in activated CD8+ cells by interacting with CD8. J. Immunol. 164:6100-6104.

11. Friese, M. A., Platten, M., Lutz, S. Z., Naumann, U., Aulwurm, S., Bischof, F., Bühring, H. J., Dichgans, J., Rammensee, H. G., Steinle, A., Weller, M. MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res. 2003; 63:8996-9006.

12. Friese, M. A., Wischhusen, J., Wick, W., Weiler, M., Eisele, G., Steinle, A., Weller, M. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antigli-oma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumori-genicity in vivo. Cancer Res. 2004; 64:7596-7603.

13. Garbi, N., Tanaka, S., van den, B. M., Momburg, F., Hammerling, G. J. Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8(+) T-cell immune responses? Immunol. Rev. 2005; 20:777-788.

14. Gasser, S., Orsulic, S., Brown, E. J., Raulet, D. H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 25(436):1186-1190.

15. Geiser, A. G., Letterio, J. J., Kulkarni, A. B., Karlsson, S., Roberts, A. B., Sporn, M. B. Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype. Proc. Natl. Acad. Sci. USA 1993; 90:9944-9948.

16. Geissmann, F., Revy, P., Regnault, A., Lepelletier, Y., Dy, M., Brousse, N., Amigorena, S., Hermine, O., Durandy, A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J. Immunol. 1999; 162:4567-4575.

17. Gerlini, G., Tun-Kyi, A., Dudli, C., Burg, G., Pimpinelli, N., Nestle, F. O. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am. J. Pathol. 2004; 165:1853-1863.

18. Girardi, M., Oppenheim, D. E., Steele, C. R., Lewis, J. M., Glusac, E., Filler, R., Hobby, P., Sutton, B., Tigelaar, R. E., Hayday, A. C. Regulation of cutaneous malignancy by gammadelta T cells. Science 2001; 294:605-609.

19. Groh, V., Bahram, S., Bauer, S., Herman, A., Beauchamp, M., Spies, T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl. Acad. Sci. USA 1996; 93:12445-12450.

20. Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K. H., Spies, T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. USA 1999; 96:6879-6884.

21. Groh, V., Wu, J., Yee, C., Spies, T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419:734-738.

22. Hayashi, T., Kobayashi, Y., Kohsaka, S., Sano, K. The mutation in the ATP binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene 2006; 25(29):4016-4026.

23. Hicklin, D. J., Marincola, F. M., Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 1999; 5:178-186.

24. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., Salih, H. R. Soluble MICA in malignant diseases. Int. J. Cancer 2006; 118:684-687.

25. Holdenrieder, S., Stieber, P., Peterfi, A., Nagel, D., Steinle, A., Salih, H. R. Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol. Immunother. 2006; 55:1584-1589.

26. Hunt, J. S. Stranger in a strange land. Immunol. Rev. 2006; 213:36-47.

27. Jinushi, M., Hodi, F. S., Dranoff, G. Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA 2006; 103:9190-9195.

28. Kim, J.-W., Wieckowski, E., Taylor, D. D., Reichert, T. E., Watkins, S., Whiteside, T. L. FasL+ membraneous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin. Cancer Res. 2005; 11:1010-1020.

29. Ko, E., Wei, L., Peng, L., Wang, X., Ferrone, S. Anti-tumor effects of anti-angiogenic immunity elicited in mice by dendritic-endothelial cell hybrids and 4-1BB-specific mAb. Cancer Res. in press 2007.

30. Kurte, M., Lopez, M., Aguirre, A., Escobar, A., Aguillon, J. C., Charo, J., Larsen, C. G.,Kiessling, R., Salazar-Onfray, F. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J. Immunol. 2004; 73:1731-1737.

31. Li, M. O., Wan, Y. Y., Sanjabi, S., Robertson, A. K., Flavell, R. A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006; 24:99-146.

32. Li, Y., Wang, M. N., Li, H., King, K. D., Bassi, R., Sun, H., Santiago, A., Hooper, A. T., Bohlen, P., Hicklin, D. J. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 2002; 195:1575-1584.

33. Lopez-Albaitero, A., Nayak, J. V., Ogino, T., Machandia, A., Gooding, W., DeLeo, A. B., Ferrone, S., Ferris, R. L. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J. Immunol. 2006; 176:3402-3409.

34. Marincola, F. M., Jaffee, E. M., Hicklin, D. J., Ferrone, S. Escape of human solid tumors from T- cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000; 74:181-273.

35. Märten, A., von Lilienfeld-Toal, M., Büchler, M. W., Schmidt, J. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int. J. Cancer 2006; 119:2359-2365.

36. Matsuda, M., Salazar, F., Petersson, M., Masucci, G., Hansson, J., Pisa, P., Zhang, Q. J., Masucci, M. G., Kiessling, R. Interleukin 10 pretreatment protects target cells from tumor-and allo-specific cytotoxic T cells and downregulates HLA class I expression. J. Exp. Med. 1994; 180:2371-2376.

37. Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B., Van Velthoven, R., Cerottini, J. C., Boon, T., Gairin, J. E., Van den Eynde, B. J. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. Immunity 2000; 12:107-117.

38. Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri., B. P., Reisfeld, R. A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002; 8:1369-1375.

39. Pende, D., Rivera, P., Marcenaro, S., Chang, C. C., Biassoni, R., Conte, R., Kubin, M., Cosman, D., Ferrone, S., Moretta, L., Moretta, A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histo-types: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002; 62:6178-6186.

40. Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., Blankenstein, T., Kiessling, R. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. 1998; 161:2099-2105.

41. Pistoia, V., Morandi, F., Wang, X., Ferrone, S. Soluble HLA-G: are they clinically relevant? Semin. Cancer Biol. 2007.

42. Puppo, F., Indiveri, F., Scudeletti, M., Ferrone, S. Soluble HLA antigens: new roles and uses. Immunol. Today 1997; 18:154-155.

43. Puppo, F., Scudeletti, M., Indiveri, F., Ferrone, S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol. Today 1995; 16:124-127.

44. Puppo, F., Contini, P., Ghio, M., Brenci, S., Scudeletti, M., Filaci, G., Ferrone, S., Indiveri, F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apop-tosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int. Immunol. 2000; 12:195-203.

45. Rabinowich, H., Suminami, Y., Reichert, T. E., Crowley-Nowick, P., Bell, M., Edwards, R., Whiteside, T. L. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Intl. J. Cancer 1996; 68:276-284.

46. Raffaghello, L., Prigione, I., Airoldi, I., Camoriano, M., Levreri, I., Gambini, C., Pende, D., Steinle, A., Ferrone, S., Pistoia, V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 2004; 6:558-568.

47. Rebmann, V., Schütt, P., Brandhorst, D., Opalka, B., Moritz, T., Nowrousian, M. R., GrosseWilde, H. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin. Immunol. 2007; 123:114-120.

48. Rouas-Freiss, N., Moreau, P., Ferrone, S. and Carosella, E. D. HLA-Gproteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005; 66:10139-10144.

49. Salazar-Onfray, F., Charo, J., Petersson, M., Freland, S., Noffz, G., Qin, Z., Blankenstein, T., Ljunggren, H. G., Kiessling, R. Down-regulation of the expression and function of the transporter associated with antigen processing in murine tumor cell lines expressing IL-10. J. Immunol. 1997; 159:3195-3202.

50. Salih, H. R., Antropius, H., Gieseke, F., Lutz, S. Z., Kanz, L., Rammensee, H. G., Steinle, A. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102:1389-1396.

51. Salih, H. R., Rammensee, H. G., Steinle, A. Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol. 2002; 169:4098-4102.

52. Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson. J. T., Whiteside, T. L. A unique subset of CD4+CD25highFoxp3+ T cells secreting IL-10 and TGF-ßj mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007.

53. Strauss, L., Whiteside, T. L., Knights, A., Bergmann, C., Knuth, A., Zippelius, A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J. Immunol. 2007; 178:320-329.

54. Sun, Y., Sijts, A. J., Song, M., Janek, K., Nussbaum, A. K., Kral, S., Schirle, M., Stevanovic, S., Paschen, A., Schild, H., Kloetzel, P. M., Schadendorf, D. Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res. 2002; 62:2875-2882.

55. Tzai, T. S., Shiau, A. L., Liu, L. L., Wu, C. L. Immunization with TGF-beta antisense oligonucleotide-modified autologous tumor vaccine enhances the antitumor immunity of MBT-2 tumor-bearing mice through upregulation of MHC class I and Fas expressions. Anticancer Res. 2000; 20:1557-1562.

56. Ugurel, S., Rebmann, V., Ferrone, S., Tilgen, W., Grosse-Wilde, H., Reinhold, U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 2001; 92:369-376.

57. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006; 66:2520-2526.

58. Whiteside, T. L. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine 2002; 20 Suppl. 4: A46-A51.

59. Wiendl, H., Mitsdoerffer, M., Hofmeister, V., Wischhusen, J., Bornemann, A., Meyermann, R., Weiss, E. H., Melms, A., Weller, M. A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J. Immunol. 2002; 168:4772-4780.

60. Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K., Plymate, S. R. Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 2004; 114:560-568.

61. Yu, P., Rowley, D. A., Fu, Y. X., Schreiber H. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 2006; 18:226-231.

62. Zavazava, N., Kronke, M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat. Med. 1996; 2:1005-1010.

63. Zeidler, R., Eissner, G., Meissner, P., Uebel, S., Tampe, R., Lazis, S., Hammerschmidt, W. Downregulation of TAP1 in B lymphocytes by cellular and Epstein-Bar rvirus-encoded interleukin-10. Blood 1997; 90:2390-2397.

Was this article helpful?

0 0
How To Bolster Your Immune System

How To Bolster Your Immune System

All Natural Immune Boosters Proven To Fight Infection, Disease And More. Discover A Natural, Safe Effective Way To Boost Your Immune System Using Ingredients From Your Kitchen Cupboard. The only common sense, no holds barred guide to hit the market today no gimmicks, no pills, just old fashioned common sense remedies to cure colds, influenza, viral infections and more.

Get My Free Audio Book


Post a comment